Technetium Tc 99m trofolastat

Drug Profile

Technetium Tc 99m trofolastat

Alternative Names: 1404; 99mTc-MIP1404; 99mTc-trofolastat; F-1311; MIP-1404; MP-1404; PSMA-targeted imaging agent 1404

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer FUJIFILM RI Pharma; Molecular Insight Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Imidazoles; Organotechnetium compounds; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Diagnostic imaging enhancers; Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 02 Jan 2018 Progenics Pharmaceuticals completes enrolment in its phase III trial for Prostate cancer (Diagnosis) in USA and Canada
  • 28 Dec 2017 Molecular Insight Pharmaceuticals completes a phase III trial in Prostate cancer (Diagnosis) in USA and Canada (IV) (NCT02615067)
  • 31 Mar 2017 FUJIFILM completes a phase IIb trial for Prostate cancer (Diagnosis) in Japan (JapicCTI163190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top